Gene-Edited cells could stop bleeding in severe hemophilia b

NCT ID NCT06611436

Recruiting now Disease control Sponsor: Be Biopharma Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times

Summary

This study tests a single dose of BE-101, a treatment made from a person's own blood cells that are gene-edited to produce clotting factor IX. It is for 24 adult men with moderately severe or severe hemophilia B who currently use preventive factor IX infusions. The goal is to see if BE-101 is safe and can reduce or stop bleeding episodes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of California, Davis
RECRUITING

Davis, California, 95616, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
Washington Center for Bleeding Disorders
RECRUITING

Seattle, Washington, 98101, United States

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA B HEMOPHILIA B, MODERATELY SEVERE OR SEVERE